Literature DB >> 18047386

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Denis Getsios1, Kristen Migliaccio-Walle, Jaime J Caro.   

Abstract

The National Institute for Health and Clinical Excellence (NICE) recently issued updated guidance on the use of cholinesterase inhibitors in the treatment of Alzheimer's disease. NICE initially recommended that cholinesterase inhibitors no longer be used, but final guidance restricted treatment to patients with disease of a moderately severe stage. This decision was based largely on results from a heavily criticised economic evaluation that used an adaptation of the Assessment of Health Economics in Alzheimer's Disease (AHEAD) model. As the developers of the AHEAD model, we examined the appropriateness of NICE's economic analyses and presentation of results. We attempted to replicate NICE's results by modifying the original AHEAD model. Sensitivity analyses were then run using the modified AHEAD model to evaluate the extent of uncertainty in predictions. The AHEAD(NICE) analyses resulted in an incremental cost-effectiveness ratio for galantamine of 82,000 pound per QALY gained (year 2003 values) from the perspective of the UK NHS and Personal Social Services. This was later revised to 46,000 pound per QALY, compared with < 9000 pound per discounted QALY gained (year 2001 values) in the original AHEAD model. Using our modified AHEAD with effectiveness estimates matching those of AHEAD(NICE), we show that NICE's choice and presentation of sensitivity analyses obscured the instability of their estimates. In the final NICE evaluation, the recommendation to delay treatment with cholinesterase inhibitors until patients have moderately severe disease was based on critical assumptions in the economic analyses that had little evidence to support them. The case of NICE's guidance on cholinesterase inhibitors highlights the importance of transparent and valid economic evaluations and the dangers of using inappropriate modelling technologies, basing analyses on a limited subset of the available data, and insufficiently reflecting the uncertainty in estimates that are intended to inform decision makers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047386     DOI: 10.2165/00019053-200725120-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  29 in total

1.  Costs of Mini Mental State Examination-related cognitive impairment.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Nick Bosanquet; Andrew Yeates
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  A taxonomy of model structures for economic evaluation of health technologies.

Authors:  Alan Brennan; Stephen E Chick; Ruth Davies
Journal:  Health Econ       Date:  2006-12       Impact factor: 3.046

Review 5.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Authors:  Hanna Kaduszkiewicz; Thomas Zimmermann; Hans-Peter Beck-Bornholdt; Hendrik van den Bussche
Journal:  BMJ       Date:  2005-08-06

Review 6.  The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

Authors:  E Loveman; C Green; J Kirby; A Takeda; J Picot; E Payne; A Clegg
Journal:  Health Technol Assess       Date:  2006-01       Impact factor: 4.014

7.  The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease.

Authors:  Steve Iliffe
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 8.  Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations.

Authors:  Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2003 Mar-Apr       Impact factor: 4.105

Review 9.  Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.

Authors:  Bengt Winblad; Vesna Jelic
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Apr-Jun       Impact factor: 2.703

10.  Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.

Authors:  Frances B Garfield; Denis Getsios; J Jaime Caro; Anders Wimo; Bengt Winblad
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more
  12 in total

1.  Estimation and validation of a multiattribute model of Alzheimer disease progression.

Authors:  Eric Stallard; Bruce Kinosian; Arthur S Zbrozek; Anatoliy I Yashin; Henry A Glick; Yaakov Stern
Journal:  Med Decis Making       Date:  2010 Nov-Dec       Impact factor: 2.583

2.  When NICE says no!

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Meandering down the road to transparency.

Authors:  Christopher I Carswell; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 5.  When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.

Authors:  Jonathan Karnon; Hossein Haji Ali Afzali
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

Review 6.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

7.  Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Authors:  Denis Getsios; Steve Blume; K Jack Ishak; Grant D H Maclaine
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Outcome measures for Parkinson's disease dementia: a systematic review.

Authors:  Samantha K Holden; Wallace E Jones; Keith A Baker; Isabel M Boersma; Benzi M Kluger
Journal:  Mov Disord Clin Pract       Date:  2015-09-16

9.  Yokukansan inhibits neuronal death during ER stress by regulating the unfolded protein response.

Authors:  Toru Hiratsuka; Shinsuke Matsuzaki; Shingo Miyata; Mitsuhiro Kinoshita; Kazuaki Kakehi; Shinji Nishida; Taiichi Katayama; Masaya Tohyama
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

10.  The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.

Authors:  Jacques Touchon; Jean Lachaine; Catherine Beauchemin; Anna Granghaud; Benoit Rive; Sébastien Bineau
Journal:  Eur J Health Econ       Date:  2013-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.